<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044338</url>
  </required_header>
  <id_info>
    <org_study_id>2020YFC2008100</org_study_id>
    <nct_id>NCT05044338</nct_id>
  </id_info>
  <brief_title>Study on Standard Evaluation System and Optimal Treatment Path of Senile Valvular Heart Disease</brief_title>
  <official_title>China Degenerative Valve Disease II Cohort Study (China-DVD2 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yongjian Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The key technology research and standard evaluation system of elderly heart valve disease&#xD;
      evaluation is to further establish a domestic multi center and large sample full information&#xD;
      big data platform of elderly heart valve disease based on the previous Chinese elderly valve&#xD;
      disease cohort and clinical research platform and the national valve disease surgery data&#xD;
      platform.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Establish clinical and Imaging Database&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>Time Frame: 2years</time_frame>
    <description>all-cause mortality</description>
  </primary_outcome>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Valvular Heart Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>imaging</intervention_name>
    <description>(1) Build the first full information big data cloud platform for diagnosis, treatment and clinical research of senile valvular disease in China (2) To establish a cohort of elderly patients with valvular disease in China and a complete database covering clinical information, functional, imaging evaluation, treatment and follow-up; (3) To analyze the clinical characteristics, functional status and imaging characteristics of senile valvular disease in China, and to understand the current situation of diagnosis and treatment; To establish a whole process standardized comprehensive evaluation system of clinical indicators of senile valvular disease combined with a variety of imaging for Chinese people.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients in each research center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with heart valve disease who are ≥ 65 years old and diagnosed by echocardiography&#xD;
        meet the requirements&#xD;
&#xD;
        One of the following criteria:&#xD;
&#xD;
          -  (1)Severe mitral stenosis: valve orifice area &lt; 1.0cm2;&#xD;
&#xD;
          -  (2)Severe mitral regurgitation: constriction neck width ≥ 7mm, or regurgitation per&#xD;
             beat (regurgitation volume)≥ 60ml, or reflux beam area / left atrial area &gt; 50%; Or&#xD;
             effective reflux port area (eroa) ≥ 0.4cm2;&#xD;
&#xD;
          -  (3)Severe aortic stenosis: mean cross valve pressure difference ≥ 40mmhg, or maximum&#xD;
             jet velocity ≥ 4m / s, orValve orifice area &lt; 1.0cm2, it should be differentiated from&#xD;
             left ventricular outflow tract stenosis;&#xD;
&#xD;
          -  (4)Severe aortic regurgitation: constriction neck width &gt; 6mm, or each pulsation&#xD;
             regurgitation ≥ 60ml, or regurgitation Flow fraction ≥ 50%, or jet width ≥ 65% of left&#xD;
             ventricular outflow tract, or effective reflux orifice area (eroa) ≥0.3cm2；&#xD;
&#xD;
          -  (5)Severe tricuspid stenosis: mean cross valve pressure difference ≥ 5mmhg;&#xD;
&#xD;
          -  (6)Severe tricuspid regurgitation: constriction neck width ≥ 7mm, or effective&#xD;
             regurgitation orifice area (eroa)≥0.4cm2；&#xD;
&#xD;
          -  (7)Severe pulmonary stenosis: the forward blood flow velocity is ≥ 4m / s, which&#xD;
             should be differentiated from right ventricular outflow tract stenosis; Severe&#xD;
             pulmonary valve regurgitation: massive regurgitation, wide constriction neck&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unwilling to accept registration and follow-up;&#xD;
&#xD;
          -  Patients with mental illness who cannot cooperate with information collection and&#xD;
             follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>yongjian wu, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital, National Center for Cardiovascular Diseases，Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>haiyan xu, doctor</last_name>
    <phone>+86 13681012249</phone>
    <email>xuhaiyan@fuwaihospital.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai Hospital, National Center for Cardiovascular Diseases，Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>haiyan xu, doctor</last_name>
      <phone>+86 13681012249</phone>
      <email>xuhaiyan@fuwaihospital.org</email>
    </contact>
    <contact_backup>
      <last_name>yongjian wu, doctor</last_name>
      <phone>+86 13701387189</phone>
      <email>fuwaihospital@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>China National Center for Cardiovascular Diseases</investigator_affiliation>
    <investigator_full_name>Yongjian Wu</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

